PCN25 COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL AS A SECOND- OR THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN KOREA
2010
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI